Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT07211932
Starting soon Observational

Tofacitinib in Juvenile Idiopathic Arthritis

NCT07211932 · tracked via the Priya Life Science Spain tracker
Sponsor
Consorci Sanitari de l'Alt Penedès i Garraf
Phase
Observational
Started
2025-12
Last updated
2025-11-26

Condition(s) studied

Juvenile Idiopathic Arthritis (JIA)

Investigational drug(s) / intervention(s)

Tofacitinib →

Tofacitinib: Patients received tofacitinib for the treatment of juvenile idiopathic arthritis (JIA).

Study summary

This study aims to evaluate, using real-world clinical practice data, the efficacy of tofacitinib in improving the clinical control of juvenile idiopathic arthritis (JIA) after 12 months of treatment.

Eligibility

Sex
ALL
Min age
—
Max age
18 Years
Healthy volunteers
No
Inclusion criteria: Diagnosis of juvenile idiopathic arthritis (JIA) documented in the medical record by the treating rheumatologist. Documentation in the medical record of the medical indication for tofacitinib treatment, with a diagnostic justification related to JIA. Age under 18 years at the time of the treatment indication with tofacitinib. Exclusion criteria: Participants diagnosed with any of the following conditions: Reactive arthritis Arthritis associated with inflammatory bowel disease Arthritis associated with another autoimmune disease

Primary outcome measure(s)

  • JADAS-10 — Baseline and 12 months
    Change in the Juvenile Arthritis Disease Activity Score (JADAS-10) score at 12 months of treatment with tofacitinib. Range score: 0 to 10, the less score the better

Trial sites (3)

FacilityCityRegionStatus
Hospital Sant Joan de Déu Barcelona Barcelona Barcelona
Corporació Sanitària Parc Taulí de Sabadell Sabadell Barcelona
Hospital de Vilafranca Vilafranca del Penedès Barceona

On this site

📄 Xeljanz (tofacitinib) drug profile →

More Consorci Sanitari de l'Alt Penedès i Garraf trials in Spain

Acetic Acid 2% Solution for Skin Ulcers Recruiting
Neuropsychological Assessment Of The Oldest-Old Population.(NEUROPSIC-GR) Recruiting
Levels of Diagnostic and Therapeutic Intervention in Hospitalized Patients Starting soon
High-risk Antithrombotic Drugs at Discharge and Consultation for Hemorrhagic or Thromboembolic Events in the Emergency Department Starting soon
Prevalence of Amyloidosis in Trauma Patients Recruiting

Other trials for the same condition

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07211932 on ClinicalTrials.gov ↗ ← All trials in Spain